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List of abbreviations 
Abbreviation Description 
ALS Amyotrophic lateral sclerosis 
ATP Adenosine triphosphate  
CHOP C/EBP homologous protein  
CNS Central neuro system  
CPA Cyclopiazonic acid  
CSF Cerebrospinal fluid  
ER Endoplasmic reticulum  
ERMCC ER-mitochondrial Ca2+cycle  
fALS Familial ALS 
FIG4  Polyphosphoinositide phosphatase 
FUS/TLS Fused-in sarcoma protein/translated in liposarcoma  
HAND HIV-associated neurocognitive disorders  
IHC Immunohistochemistry 
IRE1 Inositol-requiring enzyme1 
LMN Lower motor neuron  
LPS Lipopolysaccharide  
MNs Motor neurons  
NLRP3 Nucleotide-binding oligomerization domain receptors  
PBMC Peripheral blood mononuclear cells  
PERK Protein kinase RNA-like ER kinase  
ROS Reactive oxygen species  
RyR Ryanodine receptors  
sALS Sporadic ALS  
SERCA Sarco/endoplasmic reticulum calcium ATPase  
SETX Senataxin 
SOD1 Copper-zinc superoxide dismutase 1  
TDP-43  DNA-binding protein-43 
TLRs Toll-like receptors  
TNF- α Tumor necrosis factor  
UMN Upper motor neuron  
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UPR Unfolded protein response  
VAPB Vesicle-associated membrane protein-associated protein B 
VCP Valosin containing protein 
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Abstract 
Amyotrophic lateral sclerosis (ALS) is a heterogeneous multisystemic disease 
involving the selective loss of upper motor neuron (UMN) and lower motor neuron 
(LMN). Unsuitable environment for MNs is largely correlated to ALS pathogenesis. It 
has been shown that improving MNs´ surrounding environment at the initial stage 
could exert a protection effect. Moreover, immune abnormalities have been found in 
the blood and CSF of ALS patients. Mononuclear cells from peripheral blood have 
been revealed as a vital source for establishing disease-specific biomarkers. In ALS it 
has been described as a condition in which the endoplasmic reticulum (ER)-
mitochondria Ca2+ balance is deregulated and misfolded proteins are aggregated 
above the toxicity threshold. Similar calcium homeostasis dysfunction is also present 
in peripheral blood cells of ALS patients. In peripheral blood monoculear cells 
(PBMCs), a large variety of Ca2+ channels, receptors and Ca2+ binding protein are 
involved in the regulation of intracellular Ca2+ level. Furthermore, P2X receptors 
(P2XRs), expressed on PBMCs, are highly related to deregulate intercellular Ca2+ 
homeostasis. 
In the present dissertation the aim was to find a link between P2XRs and Ca2+ 
dysregulation in PBMCs by performing the measurement of intracellular Ca2+ levels 
in vitro. Furthermore, the Ca2+-binding protein (calnexin) expression level in 
monocytes from ALS patients was compared to controls. 
Blood samples were collected from 82 ALS patients (male=48, female=32) and 40 
age- and gender-matched controls (male=19, female=21) and used for PBMC 
isolation. The expression of P2X4R and P2X7R was analyzed by 
immunohistochemistry (IHC) and western blot. Fura-2, a ratiometric fluorescent dye 
specifically bounded to free Ca2+ was used to detect intercellular Ca2+. Moreover, 
exogenous adenosine triphosphate (ATP), inflammatory stimulus lipopolysaccharide 
(LPS) and thapsigargin were used for Ca2+ elicitation. To analyze changes in ER 
Ca2+-binding proteins of monocytes, differences in calnexin levels between patients 
and controls were measured by the integrated density. 
Western blot analyses revealed no significant difference in protein level of P2X4 
expression between patients and controls. However, the expression of P2X7R 
decreased in ALS patients compared with controls. In the monocytes from patients 
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with ALS, the increase of cytosolic Ca2+ induced by different concentrations of ATP 
was significantly lower than controls. Similarly, the Ca2+ level of controls was 
significantly higher in terms of elevation of LPS-evoked Ca2+. By contrast, 
thapsigargin-evoked Ca2+ elevation during acute sarco/endoplasmic reticulum 
calcium ATPase (SERCA) SERCA inhibition were extremely high in ALS patients. 
More abundant calnexin was visualized in monocytes from patients, suggesting an 
ER-related protein aggregation with ER stressor exposures.  
This work elucidates Ca2+ disturbance in monocytes from ALS patients. Calnexin is 
involved in the Ca2+dysregulation in monocytes during immune activation and ER 
stress. At the initial stage, aggregation exerts protective effects, but may become a 
potential cytotoxic event resulting from impaired ER at the advanced stages of ALS. 
The results also offer an explanation for overloaded Ca2+ in monocytes which may be 
buffered by an increase of Ca2+-binding protein. 
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Zusammenfassung 
Die Amyotrophe Lateralsklerose (ALS) ist eine heterogene, multisystemische 
Erkrankung, die mit dem selektiven Untergang der oberen und unteren Motoneurone 
einhergeht. Ein schädigendes Milieu in der Umgebung der Motoneurone wird als 
bedeutender Faktor in der Pathogenese der ALS gesehen. Eine Verbesserung dieser 
Umgebungsbedingungen in der initialen Phase der Erkrankung erweist sich als 
protektiv. Außerdem sind immunologische Veränderungen im Blut und Liquor von 
ALS-Patienten nachweisbar. Die Isolation von mononukleären Zellen des peripheren 
Blutes (peripheral blood mononuclear cells, PBMCs) ist eine wichtige Methode zur 
Erforschung erkrankungsspezifischer Biomarker. In der Pathologie der ALS wird ein 
Zustand beschrieben, in dem das Ca2+-Gleichgewicht zwischen Endoplasmatischem 
Reticulum (ER) und Mitochondrien dereguliert ist und fehlgefaltete Proteine oberhalb 
toxischer Konzentrationsschwellen aggregieren. Dies könnte ein Schlüsselprozess 
sein, der zum Zelluntergang von Motoneuronen führt. Ähnliche Dysregulationen in 
der Calcium-Homöostase zeigen sich auch in den peripheren Blutzellen der ALS-
Patienten. In PBMCs ist eine Vielzahl unterschiedlicher Ca2+-Kanäle, Rezeptoren und 
Ca2+-bindender Proteine vorhanden, die an der Regulation intrazellulärer Ca2+-
Konzentrationen beteiligt sind. Vor allem die auf PBMCs exprimierten P2X-
Rezeptoren (P2XRs) spielen eine große Rolle bei der Deregulation der intrazellulären 
Ca2+-Homöostase.  
Das Ziel der vorliegenden Arbeit bestand darin, eine Verbindung zwischen den 
P2XRs und der Calcium-Dysregulation in PBMCs durch die Messung intrazellulärer 
Ca2+-Konzentrationen in vitro zu finden. Außerdem wurde das Expressionslevel des 
Ca2+ bindenden Proteins Calnexin in Monozyten von ALS-Patienten gemessen und 
mit denen gesunder Kontrollen verglichen.  
Dazu wurden Blutproben von 82 ALS-Patienten (48 männliche, 32 weibliche) und 40 
alters- und geschlechtskorrelierte Kontrollpersonen (19 männliche, 21 weibliche) 
gesammelt, um PBMCs zu isolieren. Die Expression von P2X4R und P2X7R wurde 
mithilfe immunhistochemischer Färbungen und dem Western Blot-Verfahren 
analysiert. Fura-2 als radiometrischer, fluoreszierender Farbstoff, der spezifisch 
freies Ca2+ bindet, wurde verwendet, um intrazelluläres Ca2+ zu detektieren. Dabei 
wurden exogenes Adenosintriphosphat (ATP), Lipopolysaccharid (LPS) als 
inflammatorischer Stimulus und Thapsigargin genutzt, um Ca2+-Ströme zu induzieren. 
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Die Untersuchung von Veränderungen in der Konzentration Ca2+-bindender Proteine 
des ERs in Monozyten erfolgte anhand immunhistochemischer Messung des 
Calnexin-Levels in Monozyten von ALS-Patienten und Kontrollen.   
Die Auswertung der Western Blot-Ergebnisse ergab keine signifikanten Unterschiede 
im Proteinlevel der P2X4R-Expression zwischen ALS-Patienten und den 
Kontrollpersonen, wo hingegen die Expression von P2X7R bei ALS vermindert war. 
Die Monozyten der ALS-Patienten zeigten nach Induktion durch unterschiedlich hohe 
ATP-Konzentrationen einen signifikant geringeren Anstieg in der zytosolischen 
Calcium-Konzentration im Vergleich zu Kontrollen. Ebenso wurde durch LPS ein 
signifikant geringerer zytosolischer Calcium-Anstieg bei ALS-Patienten ausgelöst. Im 
Gegensatz dazu konnten massiv erhöhte Calcium-Elevationen nach Thapsigargin-
Applikation bei den Monozyten der ALS-Patienten gemessen werden, welches als 
akuter Inhibitor der Sarco/Endoplasmatisches Reticulum-Calcium-ATPase (SERCA) 
wirkte. Darüber hinaus wurde Calnexin nach Inkubation mit ER-Stressoren in 
größerem Ausmaß bei ALS-Patienten nachgewiesen, was auf eine 
Proteinaggregation im ER hinweist. 
Diese Dissertation belegt eine Störung des Calcium-Haushaltes in Monozyten von 
ALS-Patienten. Calnexin ist bei der Calcium-Dysregulation in Monozyten während 
der Immunaktivierung und des ER-Stresses involviert. Im initialen Stadium stellt die 
Proteinaggregationen zwar einen protektiven Effekt dar, kann jedoch durch Störung 
des ERs zu Zytotoxizität im fortgeschrittenem Stadium der ALS führen. Die 
Ergebnisse dieser Arbeit erklären außerdem auch die Calcium-Überladung in den 
Monozyten, was durch eine erhöhte Konzentration an Calcium bindenden Proteinen 
kompensiert sein könnte.  
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1 Introduction 
  The pathology of ALS  1.1
ALS is a rapidly progressive neurodegenerative disease. Primarily characterised by 
destruction of both upper and lower MNs in the motor cortex, brain stem and spinal 
cord, this kind of disease can lead to muscular atrophy, paralysis and respiratory 
failure (Wijesekera and Leigh, 2009). The prevalence is approximately 4-6 cases in 
100,000, with the mean age of onset between 48 and 70 years. Approximately 90% 
of ALS cases are sporadic ALS (sALS), which is the most common form of the 
disease (Gros-Louis et al., 2006). However, about 10% have genetic disorders 
clarified as hereditary ALS. Besides, more than 60% of patients die within 3-5 years 
after primary onset due to respiratory issue, while only 5-10% of patients could 
survive longer than 7 years (Heiman-Patterson et al., 2015).  
In the last decade, many studies have focused on identifying genetic mutations which 
would lead to ALS. Copper-zinc superoxide dismutase 1(SOD1) is the first gene 
which has been found with the possibility of resulting in classical adult-onset form of 
ALS (Chen et al., 2013). In ALS, there are around 20% fALS patients and 2-4% sALS 
patients are SOD1mutated ALS cases (Chen et al., 2013, Gros-Louis et al., 2006). 
Evidence of newly identified pathogenic mutations is useful for further research. For 
example, additional studies have expanded the genetic bank, including TAR (the 
transactive response), TDP-43 (DNA-binding protein-43), VCP (valosin containing 
protein), FUS/TLS (fused-in sarcoma protein/translated in liposarcoma (FUS/TLS), 
FIG4 (polyphosphoinositide phosphatase), SETX (the senataxin), UBQLN2 (ubiquitin-
like protein ubiquilin2) and VAPB (vesicle-associated membrane protein-associated 
protein B) (Chen et al., 2013), which would further provide insights into the 
mechanisms of pathogenesis in ALS (Heiman-Patterson et al., 2015). Previous 
studies showing the genetic disorders are not only concerned with fALS but also 
related to sALS. Furthermore, some neuropathological processes and mechanisms 
of sALS overlap with fALS, such as abnormal RNA metabolism, protein degradation 
and several pathogenetic pathways (Ling et al., 2013). However, the aetiologies of 
minority sALS are complex, which means diverse (Al-Chalabi and Hardiman, 2013), 
known and unknown genetic variations, epigenetics programming, gender and age 
are potentially involved (Simpson and Al-Chalabi, 2006). It is highly probable that 
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these elements may combine and interact with each other further increased risk of 
ALS by different populations at different rates.  
The diagnosis of ALS is based on clinical assessment of LMN and UMN 
degeneration, electrophysiological or neuropathologic examination, conventional 
imaging recourses, which updated by Andersen et al.  on 2015 as revised El Escorial 
criteria (Ludolph et al., 2015). With the relatively fast emergence of the clinical 
symptoms, no effective treatment is available in case when therapeutic intervention 
occurs after illness onset. In absence of cure, current therapies are largely restricted 
to symptom control, with the primary purpose of prolonging survival and improving 
quality of life as much as possible. Until now the only approved drug certified in 
different clinical trials is Riluzole (Mitsumoto et al., 2014), which is a glutamate 
antagonist and prolongs lifespan for approximately 3 months. Several drugs such as 
minocycline and creatine have been employed to extend the lifespan of animal 
models but failed on clinic trials (Gordon, 2013). Therefore, understanding the 
pathogenesis processes, early detection, fast diagnosis and individualized treatments 
are essential for improving ALS patient survival probability and reducing 
socioeconomic impacts.  
  Role of Calcium disturbances and ER stress in ALS 1.2
The pathological process that contributes to MNs death in ALS is noticeable earlier 
than the appearance of the obvious symptoms. The major mechanisms of 
pathogenesis in ALS comprise the unsuitable surrounding environment for MNs from 
spinal cord and brain, which is selectively degenerated due to either functional loss 
or changes of molecular pathway. As for the cellular pathophysiologic events include 
mitochondrial damage, oxidative stress, excitotoxicity, misfolded protein 
accumulation, inflammatory, disturbed axonal transport and activation of apoptosis-
related molecules are include (Grosskreutz et al., 2010). In fact, it has become clear 
that the abnormal Ca2+ oscillation in MNs of ALS is a prominent molecular signaling 
that implicates variously pathophysiologic function of neurodegeneration in ALS 
(Kawamata and Manfredi, 2010, Jaiswal, 2013).  
Earlier investigations have noted that Ca2+ signals, mediated by ligand- and voltage-
gated Ca2+ channels, Ca2+ transporters and also Ca2+-related proteins, could reflect 
the process of responding to various stimulations. Enhanced cytosolic calcium shows 
the Ca2+ entry through plasma membrane which induces additional Ca2+ release from 
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intracellular ER Ca2+ stores via activating IP3 receptor and ryanodine receptor 
(Clapham, 1995). In the meanwhile, the calcium pump takes Ca2+ back into the ER 
store via SERCA receptors. Moreover, the ER also interacts with adjacent organelles, 
particularly lysosome and mitochondria, maintaining a balance of internal Ca2+ 
homeostasis. According to studies in MNs of ALS, Ca2+ transforming back and forth 
between ER and mitochondria has been determined as ER-mitochondrial Ca2+ cycle 
(ERMCC) effects MNs degeneration (Grosskreutz et al., 2010). Following studies 
targeting ERMCC having demonstrated altering Ca2+-Na+ channel showed significant 
positive effects on MNs after acute exposure SOD1 over-expressed MNs to toxic 
substances (Lautenschlager et al., 2013).  
ER, as major calcium store not only modulates Ca2+ signaling, but also participates in 
protein metabolism, including protein synthesis, chaperone-assisted protein folding 
protein degradation and post-translation modification (Paschen, 2001). Based on 
previous studies, the disturbance of Ca2+ homeostasis and accumulation of misfolded 
protein would lead to functional abnormalities in ER, and this pathological process is 
termed ER stress (Schroder and Kaufman, 2005). Furthermore, a subsequent 
unfolded protein response (UPR) pathway triggered by ER stress is an adaptive 
response. In the process, misfolded protein can be accommodated to cope with ER 
stress in the prime stage. However, continuous activation of UPR pathway has 
enhanced the ER stress level, which is quite toxic to link it to apoptosis (Jaronen et 
al., 2014). Many studies demonstrated the existence of ER stress in postmortem 
tissue from ALS patients. In MNs of lumbar spinal cord from ALS patients, 
aggregated granular materials and abnormal distributed ribosomes can be observed 
in swollen and distended ER (Matus et al., 2013). In addition, several upregulated 
proteins have been involved in modulation of ER stress, so as to further describe the 
enhanced level of UPR. It has been suggested that there is a critical crosstalk 
between the accumulation of unfolded proteins and ER Ca2+ during the execution of 
UPR in ALS (Schroder and Kaufman, 2005). With the increase of Ca2+ concentration 
in ER, the Ca2+dependent protein, such as calnexin and calreticulin, can reduce ER 
stress levels by altering their protein activity (Jaronen et al., 2014).  
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 Peripheral blood mononuclear cells  1.3
1.3.1 Systemic alteration of PBMC in ALS 
Recently, it has been recognized that innate immune response is involved in ALS. 
Innate immunity is a nonspecific response which can contribute to adaptive immune 
responses. Inflammatory environment of ALS can be modulated during immune 
response through the activation of non-neuronal cells, such as microglia, astrocytes, 
monocytes and T-lymphocytes.  
PBMCs are important monitors in the circulation system. They are a mixed population 
with round nuclei, including monocytes and lymphocytes. According to various 
studies on PBMC, direct relationships have been found between activated 
mononuclear cells and neurological diseases, such as Alzheimer’s disease, 
Parkinson’s disease and HIV-associated neurocognitive disorders (HAND) (Zhou et 
al., 2012). Blood-derived immune cells can control the balance between 
immunoprotection and immunoinjury through a complex mechanism (Zhang et al., 
2005, Banati et al., 1995). PBMCs also play a crucial role in pathogenesis of ALS, as 
identified in both animal models and human.  
Mouse or rat models overexpressing genetic mutations are widely considered and 
used to study the pathology of ALS. Several studies have demonstrated a systemic 
immune activation via detecting the alternation of different population in PBMC of 
ALS. It has been examined that there is a reduced number of CD4+ T cells were 
examined in mSOD mice, including disease onset, plateau phase and end stage, 
thus showing that the state of activated PBMC is associated with disease progression 
(Beers et al., 2008). Further studies show increased CD8+ cytotoxic T lymphocyte 
appears at the end of the disease to perform immune surveillance in murine models 
of ALS (Lewis et al., 2012). Isolated PBMC from slow stage mice with special 
immunophenotypic provided a protective strategy which can prolong the survival of 
mSOD1 mice before disease onset (Zhao et al., 2012).  
Following changes were observed in rodents model of ALS, investigaitons were also 
conducted on the potential roles of PBMC in ALS patients.  It was observed that 
there was an increase in CD8+ T cell and decrease in CD4+ T cell in peripheral blood 
of ALS patients. The population of regulatory T cells was decreased as observed in 
rapidly progressing ALS patients, thereby exerting the functional role of T-cell 
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activation (Lewis et al., 2012, Rentzos et al., 2012). Down regulation of the anti-
apoptotic molecule Bcl-2 on lymphocytes suggested its protective pathway is 
deregulated in ALS (Mantovani et al., 2009, Cova et al., 2006). As suggested in 
accumulating evidence, T lymphocytes may be harmful to motor neuron through 
secretion of inflammatory cytokines, such as IL-2, IL-4, IL-6, IL-10, IL-13, IL-21 and 
INF-γ (Rentzos et al., 2012, Beers et al., 2011). Within the CNS, surrounding 
microglia and monocyte/macrophages can be damaged through the toxicity of 
cytokine produced by lymphocytes as well.  
An increasing number of evidences support that activated monocytes have been 
identified within spinal cord of patients with ALS. According to those studies, immune 
activators were significantly changed in circulating monocytes and macrophages from 
patients with ALS, which directly contributes to the pathogenesis of 
neurodegeneration (Zhang et al., 2005, Miller et al., 2014). For instance, an 
increasing level of monocyte-chemoatractant protein-1 (MCP-1) has been detected, 
which has exhibited disease severity in diagnosed ALS (Wilms et al., 2003). CCR2 is 
the dominant receptor of MCP-1 which plays an important role in the recruitment of 
monocytes/macrophages. Down-regulation of CCR2 on monocytes from ALS 
patients suggested a relationship between the activation of monocyte/macrophage 
and the deregulation of MCP-1 (Robelin and Gonzalez De Aguilar, 2014, Zhang et 
al., 2006). Inflammatory chemokines and cytokines released from activated 
monocyte may also induce injury of MNs (Sumegi et al., 2011).  
Cross-talk between lymphocyte activation and Ca2+ events has been implicated in 
lymphocytes from ALS patients. Disturbed oxidative metabolism may affect cytosolic 
Ca2+ throught the alternation of mitochondrial Ca2+ response. However, the regulation 
of Ca2+ in monocytes from ALS patients is still obscure. 
1.3.2 The importance of PBMC and biomarkers in ALS 
Although extensive researches have been carried out, regarding definition of ALS 
clinical features, an instant investigation has been conducted on the genetic 
alternation genetic alternation, neuromuscular electrodiagnostic studies, 
neurophysiology and neuroimaging features of ALS (Wijesekera and Leigh, 2009). 
Efficient tests are still in urgent need for ALS diagnosis, prognosis and follow up. A 
rapid and conclusive early diagnosis is obviously conducive, due to that it can not 
only potentially reduces the cost and duration of clinical drug trails, but also provides 
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a biological measurement for tracking the course of therapeutic intervention during 
the prodromal phase. Disease biomarkers are potential tool for the diagnosis of ALS 
at the early stage. It is common that biomarker can be obtained from various tissues 
and body fluids, such as blood, cerebrospinal fluid (CSF) and urine.  
Skeletal muscle defect is an important part of the disease process in ALS; skin would 
also represent a valuable source for the study. The tissues mentioned above are 
used for diagnosis, staging and evaluating treatment. Due to highly invasive biopsy 
procedure and accompanied pain, frequent collection of those tissues from patients 
and controls are not feasible. Accordingly, human biofluid, which is suitable for 
biomarker sources, is easily accessible. Previous published studies focused on CSF, 
serum, and the exploration of potential biomarkers of ALS. CSF is considered to 
reflect the pathogenic results in CNS (Ryberg et al., 2010). However, low protein 
concentration and invasion of lumbar puncture are disadvantages that have to be 
considered. In a recent study, gene expression profiling has demonstrated the 
feasibility of PBMCs as ideal protein source on neurodegenerative and 
neuroinflammatory studies (Achiron and Gurevich, 2006). It can be inferred from the 
obvious alteration of gene expression on PBMC-derived protein indicates that 
PBMCs become one of the key approaches to find the differentially expressed 
protein between disease and control groups. It can thus prove the great advantage 
that proteins are more stable and abundant than that obtained from CSF (Zhang et 
al., 2011, Kruger et al., 2013). Based on the proteomic analysis of PBMC from 
patients, further studies validated a series of candidate biomarkers for ALS, some of 
which were verified through diagnostic/prognostic tests and can be used to identify 
different disease states (See table 1) (Nardo et al., 2011, Mougeot et al., 2011, 
Robelin and Gonzalez De Aguilar, 2014). 
 
Table1.  Investigated Biomarkers in PBMC for ALS 
Protein name ALS-specific 
biomarkers 
ALS-progression 
biomarkers 
ALS-transnational 
biomarkers  
CLIC1 +  + 
CypA + + + 
CALR +  + 
TDP-43  +  
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GSTO1 +  + 
ERp57  +  
FUBP1   + 
mGLUR2   + 
PRDX2   + 
IRAK4 +   
Actin NT   + 
CCL2  +  
CCR2   + 
 Purinergic signaling in neurological disease  1.4
Purinergic signaling involves the activation of purinergic receptors and functional 
effects on neighbouring cells. According to the evidences from in vitro and in vivo 
experimental studies over the last decade, extracellular ATP can contribute to 
nucleotides related disturbance of purinergic signalling, which may promote 
neurodegenerative and neuroinflammatory disorders, including ALS, Alzheimer’s 
disease, multiple sclerosis, and Parkinson’s disease (Volonte et al., 2003, 
Puchalowicz et al., 2014).  
As the main energy in cells, ATP remains a relatively constant at the range of 2-5 mM 
in the cytosol. However, under physiological stresses or pathological stimulation, 
enormous amount of ATP released from stressed, apoptotic or necrotic cells into 
extracellular, is endowed with dramatic cytotoxicity and has chemotactic and 
excitatory effects on cells. Extracellular ATP modulates molecular signals through 
binding to P2 receptors (P2R), the family of this membrane receptor including 
ionotropic P2XRs and G-protein-coupled P2YRs. In this sense, there is a difference 
between different cell types and functional response to nucleotides in terms of 
expression. P2XRs containing 7 subtypes (P2X1-7) with common similar 
transmembrane structure are widely expressed in a variety of cell types. As P2XRs 
are fast ion-selective channels. These receptors regulate the influx and efflux of key 
cations, such as K+, Na+ and especially Ca2+. In CNS, ATP-evoked P2XRs activation 
in neurons can lead to an elevation of intracellular Ca2+ and cell depolarization, which 
can thus contribute to adjacent signal transduction (Figure 1). In addition, 
upregulated P2XRs are capable of moderating ATP-dependent cytokine from 
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similar structure with genetic heterogeneous contributes to coordinated functions 
(North, 2002). Indeed, P2X4 and P2X7 are usually co-expressed in immune cells 
such as microglia and recruited monocytes which has been demonstrated in the CNS 
of SOD1 mice (Apolloni et al., 2013). Both receptors have found to be up-regulated in 
microglia/macrophage from autopsy spinal cords (D'Ambrosi et al., 2009). In 
response to the inflammatory stimulation, two receptors may interact with each other 
in terms of performing surveillance. In the meanwhile, they might participate in 
apoptosis by alternation of Ca2+ homeostasis.  
 Neuorinflammation in ALS 1.5
Inflammation is a protective response against different infections, injuries or other 
pathological conditions, which in turn can lead to detrimental effects during long-term 
inflammatory process. In the CNS, systemic inflammatory activation is a prominent 
response observed in neurodegenerative processes (Pizza et al., 2011). 
Neuroinflammatory functions in ALS are common marks occurring in many cells, 
including microglia, astrocytes, T cells and monocytes. The activation of these non-
neural cells is highly involved in the pathogenesis of ALS (Rizzo et al., 2014).  
As resident macrophage, microglia presents the mainly cellular factors of immune 
response of surrounding MNs. An increasing level of cytokines and chemokines can 
induce proinflammatory profiles to promote different activations of microglia, aiming 
to prolong neuronal survival at the initial stage (Philips and Robberecht, 2011). 
However, continuous reaction of microglia may accelerate the toxicity of T cells and 
reduction of trophic factors (Rich, 1992). For instance, classically activated microglia 
display a proinflammatory phenotype which can produce IL-1β, IL-6, IL-12, IL-23, NO 
and TNF- α. It further indicates the essential role of neuronal damage in CNS already 
mentioned above. At the same time, alternatively activated microglias play a 
protective role in secreting anti-inflammatory mediators and interact with other 
immune cells like lymphocytes and monocytes, activing innate and adaptive immune 
response, reducing the release of cytokine and producing multiple neurotrophins 
(Hooten et al., 2015). Similarly, triggers of astrocytes reaction can also provoke the 
inflammatory response of MNs in surrounding microenvironment and produce 
multiple cytokines/chemokines (Glass et al., 2010). Therefore, the activation of non-
neuronal cells exerts either neurotoxic or neuroprotective effects on MNs.  
Introduction 
    16 
 
It is well characterized that LPS activates immune cells. It rapidly binds to LPS-
binding protein and initiates signals via multiple intracellular signal transduction 
pathways (Hamilton and Adams, 1987). Based on these observations, LPS-related 
signaling in different immune cells can be involved in inflammatory response by a 
systemic activation of these cells. The production of LPS-induced mediator such as 
TNF-α and NO, can amplify the inflammatory response and results in immunotoxicity. 
As for LPS-related signaling, like an indirect mediator, it can exert a selective effect of 
inducing a protective function against toxicity. Thus, selective neuronal damage may 
also be the consequence of LPS-evoked progressive neuroinflammation and 
neurodegeneration (Qin et al., 2007). Based on recent investigations, antioxidants 
can reduce the damage of neuron induced by exogenous LPS in immune cells and 
promote the production of trophic elements able to contribute to neurodegeneration 
slowdown (Tyagi et al., 2008, Rees et al., 2011). Regardless of classic stimulus in 
CNS (microglial and astrocytes activation), the LPS induced monocyte inflammatory 
response may also be associated with MNs damage.  
 Aim of the study 1.6
ALS is the most common and aggressive form of adult motor neuron (MN) 
degeneration. Several reports indicate that Ca2+ perturbation in immune cells is 
linked to dysregulation of the environment surrounding MNs but the underlying 
mechanism of how this affects PBMC is currently unknown. Rapid and conclusive 
diagnosis of ALS could be potentially determined from analysis of molecular 
pathways in PBMC. In this thesis propose that calcium perturbation in PBMC is linked 
to ALS, and that changes in the expression of purinergic receptors and ER calcium 
storage capability are the underlying mechanisms. 
The purpose of this dissertation was to test potential Ca2+ disorders in monocytes 
isolated from ALS patients. To do this, the expression of P2X4R and P2X7R was 
determined. ATP-induced Ca2+ influx via purinergic signaling regulation and LPS-
induced Ca2+ influx were examined in monocytes isolated from both ALS patients 
and control patients. Additionally, thapsgargin-triggered depletion of ER Ca2+ and the 
expression of Ca2+ binding protein calnexin that partially reflects ER calcium storage 
capability were evaluated in ALS and control patients. 
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3 Further study 
 Materials and methods  3.1
Subject consent and blood sample 
The study population was comprised of 40 patients with ALS and 21 gender- and 
age-matched healthy controls. All subjects were recruited at the University Hospital 
Jena. Revised criteria from the El Escorial World Federation of Neurology were used 
for the diagnosis of ALS. The degree of severity was measured using an outcome 
measure called the "ALS Functional Rating Scale Revised (ALSFRS-R).” The 
disease progression rate was calculated as follows: (48 -ALSFRS-R score)/disease 
duration. All subjects with a history of acute heart failure, pre-eclampsia, stroke, 
diabetic peripheral neuropathy, active infection, and those receiving anti-
inflammatory drugs, antioxidants or other treatments were excluded. 12 ml of 
peripheral blood was collected from each patient and healthy control into vacuum 
EDTA tubes (Sarstedt, Germany). The study was approved by the local ethics 
committee. 
Preparation of PBMC and culture 
Whole blood samples from patients and controls were diluted 1:2 with balanced salt 
solution (PBS) in a Leucosep tube (Greiner Bio-One, Germany). Leucosep tube 
contains biologically inert barrier and special separation medium. PBMCs were 
isolated by gradient centrifugation at 1000xg at room temperature for 10 min and the 
PBMC layer was harvested from the plasma-separation medium interface. 
Mononuclear cells were washed three times with pre-warmed PBS and isolation 
medium to remove erythrocytes. Cells were cultured by plating the PBMCs on poly-
D-lysine (Sigma, Germany)-coated 12-mm dishes (Marienfeld GmbH & Co. KG, 
Germany) in RPMI-1640 medium (Gibco, UK) supplemented with 10% heat-
inactivated fetal bovine serum (Pan-Biotech, Germany) and penicillin (10 
U/mL)/streptomycin (10 µg/mL, Gibco, UK) in an atmosphere of 5% CO2 humidified 
incubator at 37 °C. After 1 day, monocytes were separated by the adherence to the 
coverslips and thorough washing of the wells with culture media. The culture was 
maintained at a density of 100,000 cells/well.  
Induction of ER Stress  
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Cells were treated with 5µM and 10µM reversible SERCA inhibitor cyclopiazonic acid 
(CPA, Sigma, Germany) and 500nM of the irreversible SERCA inhibitor thapsigargin 
(Appli Chem, Germany) for 6 h.  
Immunocytochemistry and detection of ER stress 
Monocyte cultures were fixed in 4% paraformaldehyde (pH=7.4). After 3 washes with 
PBS, dishes were incubated with 0.3% Triton X-100 and 2% normal donkey serum 
for 2 h at room temperature to block nonspecific binding. Cultures were incubated 
overnight with mouse anti-calnexin monoclonal antibody 1:1000 (ab31290, Abcam). 
The cells were washed and incubated with the secondary antibody Alexa 488 goat 
anti-mouse. DAPI (Sigma, Germany) was applied for 5 min for the detection of the 
nucleus. The specimens were examined and recorded using the laser confocal 
scanning microscope (LSM710, Carl Zeiss Germany). This was performed for 9 cells 
per sample from at least 3 independent cultures. 
Measurements of intracellular Ca2+  
For cytosolic calcium measurements, monocytes were loaded with the membrane 
permeable ester form of the high-affinity ratiometric calcium dye fura-2AM (2uM)  
(Sigma, Germany) in the incubator at 37°C for 25 min. Incubation for additional 5 min 
at room temperature in the dark allowed the de-esterification. Following de-
esterification and washing, cells were placed onto a recording chamber and 
continuously perfused with extracellular solution containing (mM): NaCl 129.1, KCl 
5.9, glucose 11.5, MgCl2 1.2, and CaCl2 3.2 and then adjusted to pH 7.3 with NaOH. 
The fluorescence was captured by a 40×/0.8 W water immersion objective at 
excitation wavelengths of 350 and 380 nm and ratiometric fluorescent images were 
monitored by Till Vision Imaging System (TillPhotonics, Gräfelfing, Germany) with a 
CCD camera cooled to -50°C (iXONEM+, ANDOR™, Belfast, UK). The exposure 
time was set to 5 ms, the binning was 2 × 2, and the frequency for imaging was set to 
5 Hz. The concentration of free intracellular Ca2+ is proportional to the ratio of 
fluorescence at 340/380 as described by Grynkiewicz: Ca2+ concentration =KD × β × 
(R − Rmin) / (Rmax − R) where Kd = 245 nM, R = 340/380 ratio, and Rmax and Rmin are 
the 340/380 ratios under Ca2+ saturating and Ca2+ free conditions, respectively. The 
intracellular Ca2+ concentration was recalibrated after adjustment to the background. 
40ng of LPS (Sigma, Germany) or 500nM thapsigargin was applied as described 
previously (Grosskreutz et al., 2007). The extracellular solution was applied 30 
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seconds after sufficient equilibration of Fura-2. In each experiment, 1-3 cells in the 
field of view were evaluated and each subject included 9±2 replicate cells from at 
least three independent experiments. 
Statistical analysis 
Staining fluorescence intensity was quantified from each slice with same interval (Z-
stacks). Quantitative analysis of staining was performed using the software Fiji with 
the Z project plug-in. Data are represented as mean ± standard deviation (SD). 
Statistical analyses were performed using IBM SPSS Statistics 20 and Sigma plot 13. 
Distribution of groups was analyzed by Shapiro–Wilk normality and Kolmogorov-
Smirnov test. For multiple comparisons, one way ANOVA with Bonferroni correction 
was applied. Mann–Whitney-U test was used for data from non-Gaussian distribution 
and student's t-test was used for normally distributed data.  For all analysis, a p-value 
<0.05 was considered as significant.  
 Results 3.2
Characteristics of the study population 
In total, 61 subjects were recruited for this study including 40 patients (male=22, 
female=18) and 21 controls (male=8, female=13). The mean age of patients and 
controls was 59.1 (SD=11.4) years and 53.0 (SD=19.8) years, respectively. The 
mean ALSFRS-R score was 34.8 (SD=7.4). 27 patients had spinal onset ALS and 13 
had bulbar-onset ALS. The mean progression rate was 0.65 (SD=0.5).  
Monocytes of ALS patients lose the function of Ca2+ mobilization  
To investigate Ca2+ modulation under immune activation, we used LPS, a typical 
monocyte activator. LPS induced a cytosolic Ca2+ increase in monocytes from both 
patients and controls (patient subjects: n=8 patients /65 cells; control subjects: n = 11 
controls/85 cells). No differences were observed in the response rate between 
patients and controls with LPS treatment. As shown in Figure 1, intracellular Ca2+ 
increased slowly, plateaued for a short time, and then decreased gradually. 
Treatment for 3 min was sufficient for the activator to exert its maximal effects as 
indicated by the maximum peak of Ca2+ occurred around 1.5 min after the initiation of 
stimulation (Fig. 1A). The time required to reach the maximum peak height was 
similar for the two groups (data not shown). To estimate the calcium load, the area 
under the curve (AUC) was calculated (Fig. 1B). There was a marginally significant 
difference in Ca2+ dynamics between patients and controls (p<0.001; Fig. 1C).  
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Next, the changes in ER luminal Ca2+ stores were investigated.	 Following the 
exposure of monocytes to 3µM thapsigargin as performed previously, Ca2+ was 
depleted from the ER by the inhibition of the SERCAR. A steady increase in Ca2+ 
levels was detected within 3 min after the initiation of stimulation. However, Ca2+ 
levels decreased for several seconds and then remained at a high level showing 
complete emptying of the ER Ca2+ stores in both groups (Fig. 1D). The basal Ca2+ 
did not recover after 3 min of washing with extracellular solution. We observed 
significant differences in the levels of cytosolic Ca2+ between patients and controls as 
shown in Fig. 1 E by means of the AUC (p<0.001). The time required for Ca2+ to 
reach the highest value (peak amplitude/time) was significantly faster in the 
monocytes from ALS patients (p<0.001) (Fig. 1F).  
ER stress and calcium homeostasis induced changes in calnexin expression  
In the measurements, all monocytes expressed calnexin. Figure 2 shows that the 
expression of calnexin was higher in the ALS patients than in the control group. 
Following treatment with thapsigargin, the density of cytosolic calnexin was obviously 
enhanced in both patients and controls (Fig 2. A, B, G, H).  
The difference in the calnexin levels of monocytes from patient and control was 
quantified (Fig. 3). Untreated cells of patients showed higher calnexin expression 
than untreated control cells (p<0.01). After treatment with the reversible SERCA 
inhibitor cyclopiazonic acid (CPA; 5µM or 10µM) or the irreversible SERCA inhibitor 
thapsigargin (500nM), we found that the level of calnexin density in patients was 
always greater than in controls. All monocytes responded equally to the two agonists. 
Monocytes from the patient group that were treated with 10µM CPA or 0.5µM 
thapsigargin showed a significantly elevated amount of calnexin compared with the 
levels in monocytes from untreated subjects (p<0.01 and p<0.001, respectively). In 
the control group, there was no significant difference between the inhibitors (P>0.05, 
ANOVA). The treatment with thapsigargin resulted in higher calnexin expression than 
the levels in untreated control cells (p=0.035). 
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Figure1.  
The elevated Ca 2+ concentration in monocytes 
LPS 40ng was applied for 3min after 30s observation. The intercellular Ca2+ continuously 
increased in the first 1 min and then start to decrease before the application device was 
removed (A). The traces indicate the calcium levels did not return to baseline levels after 
stimulation in subjects from either group. Cytosolic Ca2+ concentration as indicated by AUC 
and peak amplitude was significantly higher in the controls (B.C). A persistent Ca2+ elevation 
was elicited by the application of 3µM thapsgargin using the same protocol as above (D). 
There was no recovery of Ca2+ after the application device was removed in subjects from 
both groups. The time (Δt) required to reach maximum Ca2+ level (peak amplitude) upon 
thapsgarain exposure indicated the fast Ca2+ release process. ER Ca2+ loading (E) and Ca2+ 
transient were higher in ALS patients (F) (*p < 0.05, **p < 0.01). 
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Figure2.  
Expression of calnexin on monocytes 
Representative immunofluorescence images of indicated ER stained with calnexin (green) 
and the nucleus was visualised with DAPI (blue). Cells from ALS patients and controls were 
grouped by untreated (A), pretreated with CPA5Μm (B), CPA10µM (C) and thapsgargin (D) 
500nM for 6 hours, respectively. 
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Figure3.  
Comparison of calnexin expression  
The expression level of calnexin on monocytes was measured by fluorescence density under 
basal condition and after treated with compounds. (*p < 0.05, **p < 0.01, ***p<0.001).
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4 Discussion  
 P2X4R and P2X7R in PBMC of ALS 4.1
P2X4R and P2X7R are key receptors that are highly expressed in immune cells and 
play a major role in cellular nucleotide metabolism, inflammasome modulation, 
immune activation, and Ca2+ signaling mediation. Previous studies reported the 
expression of P2XR in monocytes and lymphocytes (Gu et al., 2000). Further 
evidence showed that P2X4R is most highly expressed in PBMCs, followed by 
P2X7R (Wang et al., 2004).  
Due to the limitations of microglia extraction from the human body, peripheral blood 
mononuclear cells are considered as an ideal material alternative to microglia to 
study ALS in vitro. Activated monocytes are microglial precursors that normally 
impart protective immunity during the initial stages of CNS injury. P2X4R and P2X7R 
receptors can be activated by changes of stimuli or transmitters such as ATP that 
induce a rapid increase of Ca2+ in the cytosol and promote interaction between cells 
and chemokines to recruit immune cells at the site of injury. In this study, the 
distribution and expression of P2X4R and P2X7R in monocytes was ascertained by 
immunohistochemistry (IHC) and western blot.  Both the extracellular and intracellular 
components of the receptors were detectable in the monocytes from ALS patients 
and controls. This study did not find any significant difference in P2X4R expression 
between patients and controls by IHC or at the protein level by western blot. This 
result is inconsistent with the finding that P2X4R is upregulated in mutant SOD1 
microglia (Parisi et al., 2013), the different findings may be due to the different 
species and cell types used. It is very interesting that the expression of P2X4R on the 
cell surface is associated with the lysosome (Beggs et al., 2012). In addition, the CC 
chemokine receptor (CCR2) is the regulator of P2X4R, is mainly expressed on the 
surface of cells, and can control P2X4R levels via endocytosis and the degradation of 
the lysosome. Therefore, it is reasonable to infer that the levels of P2X4R protein 
might be maintained via the modulation of CCR2. The functional interaction between 
CCR2 and P2X4 in ALS requires further investigation (Zhang et al., 2006, Toyomitsu 
et al., 2012). P2X7R has been studied across various neurodegenerative diseases 
and is considered to be a target for treatment (Takenouchi et al., 2010). P2X7R may 
contribute to the expression and function of other P2 subtypes types, particularly 
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P2X4R. Studies have shown that the activation of the microglia in the ALS SOD1 
model is mediated by P2X7 (Aga et al., 2002). A defective or absent P2X7 receptor is 
associated with microglia damage and motor neuron death in SOD1 mice and an 
increase of microglia inflammatory markers including NO, iNOS, and TNFα (Kim et 
al., 2013, Valdmanis et al., 2008, Zhao et al., 2012). It was reported that the disease 
severity worsened at the end stage for P2X7R knockout SOD1 mice (Apolloni et al., 
2014). The results of this study showed that the P2X7R protein is a 75kDa protein, 
which is the full-length size of the receptor. The band seen at 65kDa is from non-
glycosylated P2X7R. Although a decrease of P2X7R expression in ALS patients was 
observed in this study, the P2X4R protein level did not change. Inhibition of P2X7R 
activation or a decrease inextracellular ATP can reduce neurotoxicity in SOD1 mice, 
suggesting that the antagonist of P2X7R might reduce neuroinflammation in ALS 
(Gandelman et al., 2010). 
Activation of the P2XR by ATP results in intracellular calcium release. To analyse the 
Ca2+ alterations in monocytes, the first experimental study was focused on the 
P2X4R receptor for two reasons: first, this subtypes clearly showed Ca2+ transients in 
the monocytes of patients with ALS; second, P2X4-like immunoreactivity was 
associated with degenerating MNs in mSOD1G93A mice (Casanovas et al., 2008). 
As a powerful and selective agonist, ATP binds to cysteine-rich loops and activates 
P2X4R over a wide range of concentrations (8–100 µM) (North, 2002). Activated 
P2X4R can trigger Ca2+ release from intracellular Ca2+ stores and activates plasma 
lemma Ca2+ influx (Yamamoto et al., 2000, Huang et al., 2014). This supports the 
model that P2X4R is highly Ca2+-permeable and directly activated by ligand binding 
linked to channel opening and fast ATP signalling (Coddou et al., 2011). P2X4 ion 
channels become increasingly permeable to Ca2+ when the application of ATP is 
continued for 50 s (Li and Fountain, 2012). To examine the Ca2+ transients in P2X4R 
activation, 10µM ATP were applied 1 minute for every 2 minutes in 3 cycles. In the 
early phase, cytosolic Ca2+ increased slowly. After 1-3 seconds, it rapidly reached 
maximal peak and then exhibited a progressive decline but failed to reach the 
previous baseline. Because no difference was observed between patients and 
controls following the initial stimulation, one can conclude that ATP-induced Ca2+ 
mobilisation reflects a compensatory reaction. Therefore, P2X4R in ALS may be 
unlikely to maintain a functional Ca2+ dynamic balance. To investigate the 
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mechanism further, a higher dose of ATP (100 µM) was applied to stimulate 
intracellular Ca2+ transients. Indeed, under regular physiological conditions, the 
oscillation of extracellular ATP was very limited. A high dose of ATP is most likely to 
be produced in pathological processes. Compared to P2X4R, P2X7R is thought to be 
specific with a relatively lower affinity for ATP. The activation of P2X7R requires high 
concentrations of ATP (≥100µM) under pathological conditions. High concentrations 
of ATP are typically used experimentally for P2X7R activation and the production of 
cytokines. Dose-dependent effects of ATP by intracellular Ca2+ were observed. The 
ALS and control samples did not differ significantly during the first cycle when ATP 
was applied at 10 µM. However, differences after applying ATP at 100 µM were 
observed. In patients, the baseline of Ca2+ mobilisation increased steadily and the 
decay of Ca2+ became progressively faster during the stimulation cycles. In striking 
contrast to the patients with ALS, the Ca2+ concentration of controls decreased 
rapidly after the peak and the baseline remained relatively high. Cytosolic Ca2+ in 
ALS patients was lower than that in the controls, implying that the capability of 
P2X4R/7R-related Ca2+ modulation in monocytes is significantly decreased in the 
ALS patients. The obtained results are consistent with the findings that P2X4R and 
P2X7R contribute to the regulation of receptor activity and Ca2+ homeostasis in 
immune cells (Smart et al., 2003, Buell et al., 1996). 
Many studies have focused on ATP signaling in immune response and the roles of 
possible regulators that are involved in the etiopathology of neurodegenerative 
process (Le Feuvre et al., 2002, Volonte et al., 2003). Extracellular ATP is released 
from damaged cells due to conditions such as hypoxia, organelle stress, and 
inflammasome activation. Accumulation of ATP is quite toxic, and ATP levels can 
regulate monocytic response by recruiting monocytes to the injured sites. This may 
suggest that systemic reduction in ATP level could be another target for treatment of 
ALS by decreasing the production of ATP or by accelerating the degradation of ATP. 
Since Ca2+ has repeatedly been described as a key player of ATP production, the 
data reported suggest a role for both P2X4 and P2X7 receptors to potentially mediate 
extracellular ATP-induced cell damage and cell death. The results of this study imply 
that P2X4- and P2X7-modulated Ca2+ perturbation participates in the damage of 
monocytes in ALS patients. 
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 Role of Ca2+ in monocytes activation in patient with ALS 4.2
The activation and recruitment of monocytes are crucial for the eradication of 
infections and inflamed tissue as part of the innate immune defense system. 
Although inflammatory responses and immune-mediated mechanisms have been 
held responsible for progression of ALS, the correlation of these processes with Ca2+ 
homeostasis is not exactly clear (Lewis et al., 2012, Zhang et al., 2009).  
An experimental study reported that exceptionally high amount of LPS and TNFα are 
present in the circulating blood of ALS patients (Cereda et al., 2008). MNs in CNS 
are susceptible to inflammatory injury after systemic exposure to LPS or TNF-α. The 
influence of LPS is to act as potentially endotoxin binding toll-like receptors (TLR) as 
part of the immune response or induce inflammation by cell activation, but also 
extends to causing an abnormal change in the levels of cytosolic Ca2+. Indeed, the 
elevation of Ca2+ indirectly results from LPS. LPS can trigger activation of monocytes, 
macrophages, and B lymphocytes and promote the release of pro-inflammatory 
factors. The activated cells lead to systemic immune response and primary Ca2+ 
release. LPS is also a potent activator of phospholipase C (PLC)-ɣ enzyme, which 
can subsequently accelerate the production of IP3. The produced IP3 binds to IP3 
receptors and then induces a second phase of Ca2+ release from the intracellular 
stores (McLeish et al., 1989). Additionally, Ca2+ could enter from the extracellular 
environment via the membrane if internal Ca2+ stores are depleted (Chiang et al., 
2012). Here, LPS was continually supplied for 3min to mimic the acute inflammatory 
process. In both subject groups, LPS-induced cytosolic Ca2+ increased slowly, and 
then after a short plateau phase, it decreased slowly and then more rapidly. The data 
indicate LPS-mediated activation of monocytes from ALS patients causes lower 
intracellular Ca2+ than controls. This result implies that immune activation may 
participate in the observed Ca2+ transient in monocytes of ALS patients and controls. 
Abnormal Ca2+ hemostasis has been described previously as an aspect of immune 
disorders (Garcia et al., 1999, Feske, 2007). Ca2+ disturbance causes cell injury and 
can initiate apoptotic pathways by inflammasome-driven activation of caspase 1 
(Lamkanfi and Dixit, 2011). Therefore, Ca2+ dysregulation may be both the outcome 
and the cause of chronic inflammatory alteration during long-term disease 
progression correlated with the pathological features of monocytes in ALS patients.  
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The data presented here shows that Ca2+ transients started to decline in the middle 
of LPS stimulation and reached baseline in 3 min. This is not consistent with the 
outcome reported by Kenneth et.el (McLeish et al., 1989) in which monocytes require 
longer (more than 5 min) incubation for LPS–induced elevation of cytosolic Ca2+, 
despite testing cells with different concentrations of LPS. Significantly lower Ca2+ 
amplitude were found in patients compared to controls. Although many factors can 
contribute to ER uptake of Ca2+, the amount of releasable Ca2+ from storage and 
extracellular matrix requires further clarification. Monocytes from ALS patients exhibit 
a lower capability to buffer the LPS-stimulated increase in Ca2+, similar to the 
response of ATP described above. Thus, it is conceivable that abnormal ATP/LPS-
induced Ca2+ levels could function as ionic signals in ALS and may be indicative of 
immune interactions in neurodegenerative disease.  
Ca2+ is a key component of physiological and pathological changes in various 
responses to insult or toxic injury and can promote repair. In addition to its 
fundamental role in monocytic activation, Ca2+ signaling also regulates 
neuroinflammation. Previous observation of long-term Ca2+ disturbances in 
monocytes demonstrated genetic changes due to activation of Ca2+-dependent 
pathways, including the IKK-NF-kB pathway, ERK (1/2) pathway, JNK pathway, and 
p38 pathway (Guha and Mackman, 2001). These pathways may therefore also be 
involved in the pathogenesis of ALS. The removal of inflammatory factors and 
maintaining functional Ca2+ dynamic balance in monocytes may be potential 
therapeutic targets for patients with ALS.  
Various neuroinflammation-related processes can cause proinflammatory cytokines 
release from monocytes, including interleukin-1α (IL-1α), IL-1β, IL-18, and TNF-α, 
through the activated P2XR pathway. ATP can be released by damaged cells and 
mediated by upregulated purinergic signaling to have effects on metabolism and 
cytotoxicity. Accumulation of ATP can act as a chemotactic factor to promote mature 
IL-1β release and Ca2+ influx via P2X7R  (Ferrari et al., 2006). P2X4R is an important 
receptor in inflammasome activation which participates in the early stage of 
inflammatory injury. Both P2X4R and P2X7R receptors can interact with the LPS-
induced pathway and can accelerate cytokine production and immune responses. At 
the same time, LPS can modulate P2X7R activity to inhibit ATP-stimulated Ca2+ 
influx and alleviate ATP-induced apoptosis (Leiva-Salcedo et al., 2011). Functional 
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interaction between P2X4R and P2X7R was shown in immune cells and activation of 
both receptors has been directly linked to IL-1β production. A burst release of IL-1β 
depends on caspase-1-related activation, TLR-induced NFkB pathway activation, 
and activation of nucleotide-binding oligomerization domain receptors (NLRP3) 
(Gong et al., 2010). Interestingly, Ca2+ plays a very complex role in the activation of 
NLRP3 in monocytes. ATP-related NLRP3 activation by P2X7R requires a basal level 
of Ca2+, but a high level of extracellular Ca2+ may inhibit NLRP3 activation (Lee et al., 
2012). Amplified NLRP3 activation can modify ER Ca2+ uptake through the SERCA 
receptor, which may attenuate ER stress and Ca2+ overload. Such Ca2+ mobilization 
is also involved in mitochondrial dysregulation and ROS production (Leiva-Salcedo et 
al., 2011). Therefore, there is potential crosstalk between calcium mobilization, the 
purinergic receptor, and inflammatory activation. As described above, consistent Ca2+ 
dysregulation was observed in monocytes from ALS patients, which suggested that 
ATP and LPS-induced Ca2+ influx are strongly related to the purinergic receptor in the 
physiological roles and pathological mechanisms of ALS. 
As pointed above, consistent Ca2+ dysregulation was observed in monocytes from 
ALS patients, which suggested that ATP and LPS-induced Ca2+ influx are strongly 
related to purinergic receptor in physiological roles and pathological mechanisms of 
ALS.  
 The regulation of ER in monocytes from ALS 4.3
This study also interested in the role of ER Ca2+ stores in monocytes from ALS 
patients. Calcium imbalance can result from dysfunction in the calcium buffering 
system, damage of intracellular Ca2+ stores, activity of Ca2+ channels, or activation of 
the Ca2+-sensing receptor. ER acts as the main intracellular Ca2+ store and Ca2+ 
storage is dependent on the activity of Ca2+ channels that allow Ca2+ transport and 
the production of Ca2+ binding proteins (Taylor et al., 2010).  
Thapsigargin is extracted from the root of thapsia garganica L and is widely used for 
studies of Ca2+ signalling in ER. Thapsgargin were applied to control luminal Ca2+ 
uptake by inhibition of SERCAs. A dramatic increase in cytosolic Ca2+ was observed 
in monocytes from both ALS patients and control subjects. This increase in Ca2+ is 
consistent with previous studies on monocytes from healthy controls (Tran et al., 
2001). Surprisingly, thapsigargin-induced Ca2+ elevation in monocytes from ALS 
patients was extremely high compared to controls. This is in contrast to the results 
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from ATP and LPS stimulation. Do SERCAs contain different functional isoforms in 
the ER to cope with Ca2+? The SERCA family includes 3 SERCA gene types: 
SERCA1 and SERCA2a are only expressed prominently in muscles and SERCA2b 
and SERCA3 are widely expressed in immune cells, and may be irreversiblely 
blocked by thapsgargin at nanomolar concentrations (Treiman et al., 1998). In 
monocytes, stimulating with thapsigargin above 100nM can induce a rapid and 
complete emptying of Ca2+ stores (Stone et al., 2000). Could other receptors 
expressed on the ER cause this change? Intracellular Ca2+-related receptors 
generally include RyR and IP3R. However, RyR is differently expressed in various 
cells. RyR1 is less prevalent in T cells and monocytes, RyR2 is only detected in CD3 
T cells, and RyR3 is not expressed in PBMCs. In addition, gene profiling of 
monocytes indicate that RyR expression is age-related, showing a decrease in both 
human and mouse with age (Stone et al., 2000). In this study, the ages of the 
enrolled subjects ranged from 48 to 70 years. This may explain the failure of the RyR 
in monocytes to mobilize Ca2+. Furthermore, thapsigargin does not increase the 
production of IP3 during the increase in intracellular Ca2+ (Putney, 1990, Treiman et 
al., 1998). Thus, neither RyR nor IP3 contribute to this mediation.  
Thapsigargin not only acts as an inhibitor of SERCA but also acts as an activator of 
inflammatory response and an inducer of ER stress (Ali et al., 1985). These 
experiments demonstrate that intracellular Ca2+ can be used as an indicator of the 
cell stress response and immune reaction. Thapsigargin-induced Ca2+ elevation in 
monocytes can activate the Ca2+ related immune response and the related Ca2+ 
receptors may enhance their permeability. Therefore, this study suggests that other 
potential mechanisms may involve ER luminal Ca2+ mobilization of monocytes in ALS 
patients.  
Free Ca2+ in the lumen of ER must be combined with special proteins. Calnexin is the 
main Ca2+-binding protein that binds Ca2+ at two sites and cooperates with SERCA to 
deal with Ca2+ oscillation and restoration. In this study, calnexin was found to be 
highly expressed in monocytes from ALS patients compared to controls. In the 
investigation of structure of Ca2+-binding proteins, calnexin binds Ca2+ affected by a 
continuous increase in free Ca2+ (Schrag et al., 2001). On the one hand, calnexin 
serves as a calcium buffer that helps relieve Ca2+ burden and activates the UPR 
(Michalak et al., 2002). On the other hand, calnexin acts as an important ER-resident 
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chaperone directly prevent protein misfolding and aggregation (Guerin et al., 2008). 
Under pathological conditions, adaptive UPR commonly mediates the activation of 
protein degradation pathways and increases the ability of ER to handle the 
accumulation of misfolded or unfolded protein. The expression of molecular 
chaperones in the ER such as calnexin and calreticulin can monitor Ca2+ binding to 
maintain Ca2+ homeostasis. However, if the ER stress is beyond control, the 
accumulation of inappropriate proteins can directly activate the apoptotic pathway 
due to poor handling of UPR (Fu et al., 2010).  
In the present study, cyclopiazonic acid (CPA) and thapsigargin were applied in 
monocytes for 6h to induce ER stress. Calnexin was expressed at higher levels in 
ALS patients compared to in the healthy controls. The ER in monocytes from the 
healthy control patients may be able to correct un/mis-folded protein via UPR. In 
thapsigargin-treated monocytes, the expression of calnexin was higher than in the 
CPA treated cells. This may be because CPA is a reversible inhibitor and 
thapsigargin is a completely irreversible stressor that leads to ER Ca2+ depletion, 
organelle damage, and cell death. The study correlates the finding from thapsigargin-
induced Ca2+ release with calnexin expression. These results demonstrated that 
Ca2+-binding protein plays an essential role in Ca2+ homeostasis to cope with Ca2+ 
dysregulation of monocytes in patients with ALS. 
5 Conclusion and clinical potential 
This study suggests Ca2+ is a key component in ALS. Here determined that Ca2+ 
dysregulation in ALS is not only present in MNs but also in immune cells. Monocytes 
from patients with ALS seem to lose the functional modulation of Ca2+ homeostasis.  
Two common monocyte activators, LPS and ATP, were used to elicit the cytosolic 
Ca2+ response. Dose-dependent activation of ATP was shown. This process 
appeared linked to both P2X4R and P2X7R and related to Ca2+ homeostasis. These 
results indicate crosstalk between immune response and the purinergic pathway. The 
intimate relationship between purinergic activation and Ca2+ signaling suggests that 
the altered sensitivity of P2X4/7R is involved in functional dysregulation of monocytes 
in patients with ALS.  
Events that cause Ca2+ imbalance are crucial in the pathogenesis of ALS. 
Intracellular Ca2+ stores and buffer capacity in monocytes were measured. The 
Discussion 
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results suggest that accumulation of Ca2+-binding protein in monocytes from ALS 
patients can act as dynamic buffers by binding to overloaded Ca2+ in the ER lumen. 
This further strengthened the point that the surrounding environment of MNs such as 
immune cells is an important pathogenic factor that cannot be ruled out. One of the 
limitations of this study is that patients were not divided into groups by different 
stages of the disease. Clinical heterogeneity and strict rules about enrollment are the 
main reasons behind this limitation.  
Overall, the discovery of Ca2+ signaling dysregulation in monocytes from patients with 
ALS presents increased opportunities for understanding the pathogenesis of ALS. 
Based on the immune-modulated mechanism of neurodegeneration, measurement of 
Ca2+ levels can be used to detect and complement the therapeutic potentials of ALS.   
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